AtriCure Inc To Host an Investor Education Webcast Transcript
(technical difficulty) Of Certain remarks that may include forward-looking statements, as we've noted in the accompanying slide.
In AtriCure's first investor education webcast, we are really excited to have 2 key opinion leaders for the Convergent Hybrid AF therapy with us today to share their experience with program development and expansion.
As many of you know, this therapy was launched last year following the PMA approval of the EPi-Sense system for treatment of patients with long-standing persistent Afib.
This approval resulted from the groundbreaking CONVERGE trial which demonstrated the superiority of Hybrid AF therapy using the EPi-Sense device to endocardio catheter ablation alone. The accompanying slide illustrates some of the key takeaways from the CONVERGE trial and notably, the durability and (inaudible) efficacy of the procedure while also providing significant burden reduction for long-standing persistent patients, and time savings for EPs with these difficult and complex cases.
We believe these results are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |